Fujifilm Biotechnologies expanded its US biomanufacturing footprint in Holly Springs, North Carolina, aligning with FDA’s PreCheck Pilot Program selection for commercial-scale cell culture facilities. The company’s Holly Springs operations include a $3.2 billion end-to-end biomanufacturing investment and further capacity expansion plans for additional mammalian cell culture bioreactors. Coverage also highlights an announced customer commitment for second-phase manufacturing support for argenx’s efgartigimod alfa-fcab programs across generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy. Alongside production expansion, Fujifilm opened a quality control laboratory in Hillerød, Denmark, adding viral safety testing and other release-related capabilities. The moves reinforce ongoing demand for scalable, compliant capacity from developers of antibody and other cell-based modalities.